以颈部肿块为首发症状的套细胞淋巴瘤的临床分析  

The clinical analysis of mantle cell lymphoma with cervical mass as the first symptom

作　　者：梁锦辉[1] 黄河浪[1] 李莉[1] 李华[1] 罗海林[1] 黄梅[1] 庞礴 高山[3] 毛谓东 林忠菊 张美羽 LIANG Jinhui;HUANG Helang;LI Li;LI Hua;LUO Hailin;HUANG Mei;PANG Bo;GAO Shan;MAO Weidong;LIN Zhongju;ZHANG Meiyu(Department of Otolaryngology Head and Neck Surgery,Hanzhong Central Hospital,Hanzhong,Shaanxi,723000,China)

机构地区：[1]陕西省汉中市中心医院耳鼻咽喉头颈外科,汉中723000 [2]陕西省汉中市中心医院病理科 [3]陕西省汉中市中心医院放疗科

出　　处：《中国中西医结合耳鼻咽喉科杂志》2020年第6期454-457,共4页Chinese Journal of Otorhinolaryngology in Integrative Medicine

摘　　要：目的探讨以颈部肿块为首发症状的套细胞淋巴瘤(MCL)的临床诊断、治疗及预后,提高对MCL的认识。方法结合文献对11例MCL患者的诊治过程进行回顾性分析。结果11例患者存活时间超过1年者10例,超过3年者7例,超过5年者2例。结论以颈部肿块为首发症状的MCL预后不良,是一种高度恶性的淋巴瘤,尽早行病理学检查,以利妥昔单抗联合CHOP的化疗方案能提高其3年生存期。Objective To investigate the clinical diagnosis,treatment and prognosis of mantle cell lymphoma(MCL)with cervical mass as the first symptom,to improve the understanding of MCL.Method Combined with literature,the diagnosis and treatment process of 11 cases of MCL were retrospectively analyzed.Result Ten of the 11 patients survived for more than 1 year,seven for more than 3 years,and two for more than 5 years.Conclusion MCL with cervical mass as the first symptom has a poor prognosis and is a highly malignant lymphoma.Pathological examination should be completed as early as possible.Chemotherapy regimen of rituximab combined with chop can improve the 3-year survival period.

关 键 词：颈部肿块 套细胞淋巴瘤 利妥昔单抗 

分 类 号：R739.91[医药卫生—肿瘤]